Current Duke Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2000 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Initial testing of a mobile app behavioral pain coping intervention for patients with cancer: Results of a pilot randomized controlled trial.
Journal article J Psychosoc Oncol · April 8, 2026 OBJECTIVES: Behavioral management is recommended for cancer pain, yet not well integrated into clinical practice. PainPac is an asynchronous mobile application that delivers behavioral pain coping strategies. We evaluated PainPac's feasibility, acceptabili ... Full text Link to item CiteMonitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.
Journal article Sci Rep · March 23, 2026 To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to ... Full text Link to item CiteAuthor Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.
Journal article Nat Commun · February 6, 2026 Full text Link to item CiteRecent Grants
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinom
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2025 - 2030[M24-977] A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gas
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2029A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Clinical TrialPrincipal Investigator · Awarded by Arcus Biosciences · 2022 - 2027View All Grants
Education
State University of New York, Buffalo ·
2000
M.D.